Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 18/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 12/20 | 0.57 |
| ▸ | CCR7 | P32248 | 1/20 | 0.50 |
| ▸ | CCR6 | P51684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14639919 | 0.92 | CXCR2 (0.54) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL13208139 | 0.90 | CXCR2 (0.72) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL13208725 | 0.89 | CXCR2 (0.71) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL13207013 | 0.87 | CXCR2 (0.57) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL13344833 | 0.86 | CXCR2 (0.69) | CXCR2CXCR1LMNATSHRSMN1; SMN2 | |
| SCHEMBL13207800 | 0.86 | CXCR2 (0.56) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL14621827 | 0.86 | CXCR2 (0.53) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12779771 | 0.86 | CXCR2 (0.56) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL13344836 | 0.86 | CXCR2 (0.71) | CXCR2CXCR1CCR7 | |
| SCHEMBL14619901 | 0.86 | CXCR2 (0.52) | CXCR2CXCR1CCR7CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718678-B2 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718678-B2 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-20070004682-A1 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20070004682-A1 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004682-A1 | Di-substituted oxadiazoles as CXC-chemokine receptor ligands | CXCR3, CXCR1, CXCR2 | CXCR2 3/4885CXCR1 2/4885CCR7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.